Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMedizinische Hochschule Brandenburg Theodor Fontane

About this trial

Development, validation and evaluation of a new multimodal questionnaire to assess and quantify the abdominal involvement in patients with the inherited life shortening multi-organ disease Cystic fibrosis.

In the stepwhise development of the patient reported outcome measures (PROM) repeadedly, CF-patients, their families as well as professionals working in different fields of CF-care will be included.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

a sweat chloride of >60 mEq/L and/or

detection of 2 disease causing CFTR mutations with evidence of organ involvement.

Age-matched

Disqualifiers

Lacking ability to cooperate of patients /their families, respectively

Other diseases causing abdominal symptoms (Inflammatory bowel disease (IBD), alpha 1 antitrypsin deficiency, celiac disease, food allergy, gastroenteritis, etc.)

Trial population

Patients with CF of all ages

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Questionnaire Patient Reported Outcome Measure (PROM)

    Diagnostic test

    non-interventional

Treatment groups

2,000 Participants
are divided into 2 treatment groups
Group A: Patients with CF1 intervention
Group B: Age-matched healthy controls1 intervention

Trial outcomes

Primary outcomes

1

Development and evaluation of the CFAbd-Score (initially named JenAbdomen CF-Score), a CF-specific PROM following FDA recommendations

Evaluation and validation of the CFAbd-Score based on a CF patient-reported outcome measure (PROM) that includes all relevant gastrointestinal symptoms and their impact on subjective quality of life

Time frame
7 years
2

Development and evaluation of a diary for assessment and quantification of abdominal symptoms, a CF-specific PROM following FDA recommendations

Time frame
7

Secondary outcomes

1

Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings

relating CFAbd-Scores to history, clinical- and laboratory findings

Time frame
7 years
2

Assessing the Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients

abdominal ultrasound

Time frame
3 years
3

Effects of a new therapy with CFTR-modulator on abdominal symtoms, quantified with the CFAbd-Score

Assessing the CFAbd-Score´s sensitivity to identify and quantify changes due to effective therapeutic interventions, following FDA-guidelines for validation of a PROM

Time frame
7 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.